Diagnostik & Forschungszentrum für Molekulare BioMedizin

Molecular pathogenesis of lung diseases

Research focus

NEUROENDOCRINE TUMORS IN LUNG AND MEDISTINUM

  • Molecular characterization of neuroendocrine tumors in lung and mediastinum (collaboration with P. Ströbel, Göttingen and L. Fernandez-Cuesta, Lyon, IACR)
  • Proliferation markers in lung carcinoids (Graz+Zagreb)
  • DLL (Delta like) 3 in neuroendocrine tumors of the lung (Graz)
Most exciting results
  • Lung: supra-carcinoids identified, with carcinoid-like morphology, but molecular and clinical features of LCNEC, supporting molecular link between the low- and high-grade lung neuroendocrine neoplasms
  • Thymus: NETs fall into three molecular subgroups, not reflected by the WHO classification. A morphomolecular grading system is proposed, instead of histologic classification for patient stratification and prognostication.
Publications
  • Dinter H, et al. Molecular Classification of Neuroendocrine Tumors of the Thymus. J Thorac Oncol. 2019 Aug;14(8):1472-1483.
  • Brcic L, et al. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures. Diagn Pathol. 2019 May 20;14(1):47.
  • Brcic L, et al. Prognostic value of cyclin A2 and B1 expression in lung carcinoids. Pathology. 2019 Aug;51(5):481-486.
  • van Seijen M, et al. Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. Virchows Arch. 2019 Aug;475(2):191-199.
  • Mohrherr J, et al. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. Int J Cancer. 2019 Dec 15;145(12):3376-3388. doi: 10.1002/ijc.32624. Epub 2019 Sep 10.
  • Alcala N, et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun. 2019 Aug 20;10(1):3407. doi: 10.1038/s41467-019-11276-9.
  • Seidl C, et al. MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Lett. 2019 Nov 4. pii: S0304-3835(19)30547-6.
Future plans - MESOTHELIOMA RESEARCH
  • Analysis of the new marker of CDKN2A (p16) deletion- MTAP
  • MesoViBe- Mesothelioma Virtual Bank Austria
  • Molecular profiling of mesothelioma in young patients (<50y)
  • TEXT
  • TEXT
  • TEXT
  • TEXT
  • TEXT